- Home
- HTH vs HCM Comparison
HTH vs HCM Comparison
Compare HTH & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | HCM |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | HTH | HCM |
|---|---|---|
| Price | $38.28 | $11.20 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.50 | $13.75 |
| AVG Volume (30 Days) | ★ 275.1K | 46.9K |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | $3.22 | $15.62 |
| P/E Ratio | $59.75 | ★ $5.49 |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $29.20 | $9.77 |
| 52 Week High | $40.41 | $19.50 |
Technical Indicators
Market Signals| Indicator | HTH | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 51.39 |
| Support Level | $36.32 | $9.77 |
| Resistance Level | $38.52 | $11.81 |
| Average True Range (ATR) | 0.77 | 0.27 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 35.19 | 46.23 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.